Business
WuXi Biologics Reports Solid 2025 Interim Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2025 ("Reporting Period").
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2%","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"IFRS Gross profit margin expanded by 3.6% YoY to 42.7%","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased 11.6% YoY","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"FY25 group revenue growth target raised to 14% – 16%","length":52,"tagName":"p"}]},{"val":[{"type":"text","content":"A first-half record of 86 new integrated projects added, including 2 in late-stage","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Total integrated projects reached 864, one of the largest portfolios of complex biologics","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Late-stage and CMO revenue rose 24.9% YoY; 25 PPQs scheduled for 2025","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Total backlog increased to US$20.34 billion; backlog within 3 years increased to US$4.21 billion","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Optimized global operations and enhanced capacities to support sustainable growth","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":784,"olType":false},{"type":"text","content":"HONG KONG, Aug. 19, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2025 ("Reporting Period").","length":446,"tagName":"p"},{"type":"text","content":"Financial Highlights","length":20,"tagName":"p"},{"type":"text","content":"Revenue: The Group's revenue for the Reporting Period increased by 16.1% YoY to RMB9,953.2 million. The growth was primarily driven by: (i) the continued success of the Group's "Follow and Win the Molecule" strategies, supported by its leading technol...